Stockscreener 앱 받기
2.35
2.89%
-0.07
전일 마감가:
$2.42
열려 있는:
$2.42
하루 거래량:
85,597
Relative Volume:
0.62
시가총액:
$112.21M
수익:
순이익/손실:
$-293.42M
주가수익비율:
-0.0806
EPS:
-29.1639
순현금흐름:
$-14.87M
1주 성능:
-26.10%
1개월 성능:
-32.57%
6개월 성능:
-62.64%
1년 성능:
-7.13%
1일 변동 폭
$2.30
$2.47
1주일 범위
$2.28
$3.23
52주 변동 폭
$2.28
$12.46
미네르바 뉴로사이언스 Stock (NERV) Company Profile
명칭
Minerva Neurosciences Inc
전화
617-600-7373
주소
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
2.35 | 112.21M | 0 | -293.42M | -14.87M | -29.16 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
미네르바 뉴로사이언스 Stock (NERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-14 | 업그레이드 | Jefferies | Hold → Buy |
| 2026-04-15 | 개시 | Citizens | Mkt Outperform |
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 개시 | BTIG Research | Buy |
| 2019-10-02 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-25 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-31 | 개시 | H.C. Wainwright | Buy |
| 2017-09-01 | 개시 | Citigroup | Buy |
| 2017-03-06 | 재개 | Jefferies | Buy |
| 2016-05-12 | 재개 | Jefferies | Buy |
모두보기
미네르바 뉴로사이언스 주식(NERV)의 최신 뉴스
Anthony Aliquo Net Worth (2026) - GuruFocus
Minerva Neurosciences Inc. Stock Grades | NERV - Barron's
Minerva Neurosciences Inc Share PriceNERV, RNS News, Articles, Quotes, & Charts (NASDAQ:NERV) - Proactive financial news
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to S&P Global BMI Index - marketscreener.com
Minerva Neurosciences at Cantor conference: roluperidone reset By Investing.com - Investing.com Nigeria
Minerva Neurosciences at Cantor conference: roluperidone reset By Investing.com - Investing.com Canada
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageRevenue Breakdown Analysis - siam.in
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageEPS Consistency Score - dars.gov.et
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageEarnings Seasonality - dars.gov.et
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageGuidance Accuracy Score - https://www.dars.gov.et/
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageAnalyst Earnings Estimate - dars.gov.et
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - Investing News Network
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - kommunikasjon.ntb.no
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - Yahoo Finance
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - The Manila Times
Minerva (NERV): Loses 0.62% to Close at $4.81 in Latest Trading; Level Watch: the $4.57 to $5.05 Range Remains in Focus for the Current SessionBearish Pattern Stocks - careplusvn.com
Minerva Neurosciences Inc (NASDAQ: NERV) Share Price, NERV Stock News, NERV Share Price & Updates - Kalkine
Balyasny Asset Management L.P. Expands Stake in Minerva Neurosciences Inc (NERV) - GuruFocus
Minerva Neurosciences (NASDAQ: NERV) COO holds 20,872 shares, 750K and 680K options - Stock Titan
NERV Upgraded by Jefferies -- Price Target Raised to $10.00 - GuruFocus
Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages - marketbeat.com
Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants - Stock Titan
Jefferies Upgrades Minerva Neurosciences(NERV.US) to Buy Rating, Raises Target Price to $10 - Moomoo
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com Canada
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com India
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com UK
Jefferies Maintains Minerva Neurosciences(NERV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants - Stock Titan
Minerva Neurosciences (NERV) Advances to $3.99, Holding Support as Resistance at $4.19 LoomsHot Stock Picks - vinanet.vn
Minerva Neurosciences (NERV) Advances to $3.99, Holding Support as Resistance at $4.19 LoomsNHNL Ratio - careplusvn.com
Minerva Neurosciences (NERV) Plunges 9% to $3.92: Critical Support Level in FocusTotal Put Call - siam.in
Minerva Neurosciences Elevates Aliquo to Accounting Leadership - TipRanks
Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role - Stock Titan
HC Wainwright Has Bearish Estimate for NERV Q3 Earnings - MarketBeat
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen - MarketBeat
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Nigeria
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com South Africa
Minerva Neurosciences Q2 adjusted EPS beats estimates on warrant gain - scanx.trade
Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates - TradingView
Minerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary - TradingView
Minerva Neurosciences (NASDAQ: NERV) logs $107.9M loss but holds $75.4M cash - Stock Titan
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Canada
Minerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M - TradingView
Minerva Neurosciences: Q2 Earnings Snapshot - marketscreener.com
Minerva Neurosciences: Q2 Earnings Snapshot - Barchart.com
Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues - Quiver Quantitative
미네르바 뉴로사이언스 (NERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
미네르바 뉴로사이언스 주식 (NERV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Federated Hermes Kaufmann Smal | 10% Owner |
Mar 31 '26 |
Proposed Sale |
8.00 |
19,838 |
158,704 |
0 |
| Federated Hermes Kaufmann Fund | 10% Owner |
Mar 31 '26 |
Proposed Sale |
8.00 |
31,808 |
254,464 |
0 |
| Federated Hermes Kaufmann Fund | 10% Owner |
Mar 10 '26 |
Proposed Sale |
8.00 |
12,456 |
99,648 |
0 |
| Federated Hermes Kaufmann Smal | 10% Owner |
Mar 10 '26 |
Proposed Sale |
8.00 |
264,615 |
2,116,920 |
0 |
| Federated Hermes Kaufmann Fund | 10% Owner |
Mar 10 '26 |
Proposed Sale |
8.00 |
424,278 |
3,394,224 |
0 |
4.22%
자본화:
|
볼륨(24시간):